VOYA Investment Management’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-409,539
| Closed | -$19.4M | – | 2409 |
|
|
2025
Q3 | $19.4M | Sell |
409,539
-7,884
| -2% | -$382K | 0.02% | 507 |
|
|
2025
Q2 | $22.3M | Buy |
417,423
+334,952
| +406% | +$15.2M | 0.02% | 504 |
|
|
2025
Q1 | $3.34M | Buy |
82,471
+62,000
| +303% | +$2.63M | ﹤0.01% | 1109 |
|
|
2024
Q4 | $570K | Sell |
20,471
-1,560
| -7% | -$47.2K | ﹤0.01% | 1883 |
|
|
2024
Q3 | $632K | Sell |
22,031
-573
| -3% | -$14.9K | ﹤0.01% | 1879 |
|
|
2024
Q2 | $530K | Buy |
22,604
+2,911
| +15% | +$62.3K | ﹤0.01% | 1967 |
|
|
2024
Q1 | $497K | Sell |
19,693
-613
| -3% | -$14.7K | ﹤0.01% | 2021 |
|
|
2023
Q4 | $474K | Sell |
20,306
-13,305
| -40% | -$262K | ﹤0.01% | 2109 |
|
|
2023
Q3 | $1.7M | Buy |
33,611
+2,553
| +8% | +$119K | ﹤0.01% | 1396 |
|
|
2023
Q2 | $1.45M | Buy |
31,058
+4,653
| +18% | +$213K | ﹤0.01% | 1483 |
|
|
2023
Q1 | $1.01M | Sell |
26,405
-10,360
| -28% | -$462K | ﹤0.01% | 1653 |
|
|
2022
Q4 | $2.01M | Buy |
36,765
+25,818
| +236% | +$1.11M | ﹤0.01% | 1328 |
|
|
2022
Q3 | $373K | Hold |
10,947
| – | – | ﹤0.01% | 2215 |
|
|
2022
Q2 | $103K | Buy |
10,947
+784
| +8% | +$8.17K | ﹤0.01% | 2608 |
|
|
2022
Q1 | $144K | Hold |
10,163
| – | – | ﹤0.01% | 2440 |
|
|
2021
Q4 | $215K | Buy |
10,163
+96
| +1% | +$2.13K | ﹤0.01% | 2471 |
|
|
2021
Q3 | $225K | Hold |
10,067
| – | – | ﹤0.01% | 2497 |
|
|
2021
Q2 | $250K | Buy |
+10,067
| New | +$283K | ﹤0.01% | 2469 |
|
Other funds holding AKRO
VOYA Investment Management's AKRO Position: Q4 2025 in Review
VOYA Investment Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 409,539 shares — an estimated $19.4M sold.
VOYA Investment Management first reported a position in AKRO in Q2 2021 and held it in 18 quarters. The position peaked at $22.3M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- VOYA Investment Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- VOYA Investment Management sold 409,539 Akero Therapeutics shares in Q4 2025, an estimated $19.4M.
- VOYA Investment Management first reported a position in Akero Therapeutics in Q2 2021 and held it in 18 quarters.
- VOYA Investment Management's Akero Therapeutics position peaked at $22.3M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on VOYA Investment Management's 13F filing for Q4 2025, filed 12 Feb 2026.